David Dean Halbert

David Dean Halbert (#1678)

I fundamentally believed that if there was something wrong with the human body, there was something misfiring at the molecular level and technology advances could find that and diagnose it and possibly treat it.

$ 3 B
Biotech
United States
M
70 Years

About Me

David Dean Halbert became a billionaire in June 2025 when the diagnostics firm he built up, Caris Life Sciences, went public on the Nasdaq. In 2008 Halbert acquired a small biotech firm called Molecular Profiling Institute, then greatly expanded it and renamed it Caris Life Sciences; he owns a 44% stake. Caris Life Sciences uses gene sequencing, AI and machine learning for early disease detection; revenue at the unprofitable company grew to $412 million in 2024. Halbert previously founded pharmacy benefit manager AdvancePCS in 1987. He took it public and later sold it to Caremark for $7.5 billion in 2004 He has been an active buyer and seller of healthcare businesses through his Caris Capital.

Achievements

Career Highlights

A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped David Dean Halbert’s rise and global influence.

#1611 Billionaires (2026)
#308 Forbes 400 (2025)

Wealth Growth

Net Worth Growth Over Time

Tracking David Dean Halbert’s net worth journey over the years, highlighting key growth phases and financial milestones.